FDA Warns That Type 2 Diabetes Medicines Called SGLT2 Inhibitors Such As Invokana May Result Ketoacidosis and Hospitalization
The Federal Drug Administration (FDA) is warning that the class of Type 2 Diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors, which includes Invokana, Invokamet, Farxiga, Xigduo XR, Jardiance, and Glyxambi, may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids and may require hospitalizations. Twenty cases have been reported from March 2013 to June 6, 2014.
If you, a family member, or friend have taken Invokana or any of the other SGLT2 Inhibitors, you/they may have a claim. Please contact The Julian C. Gomez Law Firm. We may be able to help.